A randomised, double blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of bevacizumab in combination with docetaxel compared with docetaxel plus placebo, as first line treatment for patients with HER2 negative metastatic and locally recurrent breast cancer

Trial Profile

A randomised, double blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of bevacizumab in combination with docetaxel compared with docetaxel plus placebo, as first line treatment for patients with HER2 negative metastatic and locally recurrent breast cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AVADO
  • Sponsors Roche
  • Most Recent Events

    • 01 Jan 2013 New source identified and integrated (United Kingdom Clinical Research Network: 2607).
    • 18 Apr 2011 Planned End Date changed from 1 Dec 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 18 Sep 2010 The FDA has extended the review period, of results from this trial, for Genentech's supplemental Biologics Licence Application until 17 Dec 2010 according to a Genentech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top